Literature DB >> 16584714

Enzymatic characterization of O-GlcNAcase isoforms using a fluorogenic GlcNAc substrate.

Eun Ju Kim1, Dae Ook Kang, Dona C Love, John A Hanover.   

Abstract

A highly sensitive fluorogenic hexosaminidase substrate, fluorescein di(N-acetyl-beta-D-glucosaminide) (FDGlcNAc), was prepared essentially as described previously [Chem. Pharm. Bull. 1993, 41, 314] with some modifications. The fluorescent analog is a substrate for a number of hexosaminidases but here we have focused on the cytoplasmic O-GlcNAcase isoforms. Kinetic analysis using purified O-GlcNAcase and its splice variant (v-O-GlcNAcase) expressed in Escherichia coli suggests that FDGlcNAc is a much more efficient substrate (Km = 84.9 microM) than the conventional substrate, para-nitrophenyl 2-acetamido-2-deoxy-beta-D-glucopyranoside (pNP-beta-GlcNAc, Km = 1.1 mM) and a previously developed fluorogenic substrate, 4-methylumbelliferyl 2-acetamido-2-deoxy-beta-D-glucopyranoside [MUGlcNAc, Km = 0.43 mM; J. Biol. Chem. 2005, 280, 25313] for O-GlcNAcase. The variant O-GlcNAcase, a protein lacking the C-terminal third of the full-length O-GlcNAcase, exhibited a Km of 2.1 mM with respect to FDGlcNAc. This shorter isoform was not previously thought to exhibit O-GlcNAcase activity based on in vitro studies with pNP-beta-GlcNAc. However, both O-GlcNAcase isoforms reduced O-GlcNAc protein levels extracted from HeLa and HT-29 cells in vitro, indicating that the splice variant is a bona fide O-GlcNAcase. Fluorescein di-N-acetyl-beta-D-galactosaminide (FDGalNAc) is not cleaved by these enzymes, consistent with previous findings that the O-GlcNAcase has substrate specificity toward O-GlcNAc but not O-GalNAc. The enzymatic activity of the shorter isoform of O-GlcNAcase was first detected by using highly sensitive fluorogenic FDGlcNAc substrate. The finding that O-GlcNAcase exists as two distinct isoforms has a number of important implications for the role of O-GlcNAcase in hexosamine signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16584714     DOI: 10.1016/j.carres.2006.03.004

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  40 in total

1.  Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.

Authors:  Wei Zheng; Janak Padia; Daniel J Urban; Ajit Jadhav; Ozlem Goker-Alpan; Anton Simeonov; Ehud Goldin; Douglas Auld; Mary E LaMarca; James Inglese; Christopher P Austin; Ellen Sidransky
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

2.  Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain.

Authors:  Sarah Förster; Andrew S Welleford; Judy C Triplett; Rukhsana Sultana; Brigitte Schmitz; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2014-05-23

3.  A genetic model to study O-GlcNAc cycling in immortalized mouse embryonic fibroblasts.

Authors:  Melissa M St Amand; Michelle R Bond; Julia Riedy; Marcella Comly; Joseph Shiloach; John A Hanover
Journal:  J Biol Chem       Date:  2018-06-28       Impact factor: 5.157

4.  Nutrient-driven O-GlcNAc cycling - think globally but act locally.

Authors:  Katryn R Harwood; John A Hanover
Journal:  J Cell Sci       Date:  2014-04-24       Impact factor: 5.285

5.  Structures of human O-GlcNAcase and its complexes reveal a new substrate recognition mode.

Authors:  Baobin Li; Hao Li; Lei Lu; Jiaoyang Jiang
Journal:  Nat Struct Mol Biol       Date:  2017-03-20       Impact factor: 15.369

6.  Dynamic O-GlcNAcylation and its roles in the cellular stress response and homeostasis.

Authors:  Jennifer A Groves; Albert Lee; Gokben Yildirir; Natasha E Zachara
Journal:  Cell Stress Chaperones       Date:  2013-04-26       Impact factor: 3.667

Review 7.  O-GlcNAc cycling: emerging roles in development and epigenetics.

Authors:  Dona C Love; Michael W Krause; John A Hanover
Journal:  Semin Cell Dev Biol       Date:  2010-05-19       Impact factor: 7.727

8.  Recognition of diazirine-modified O-GlcNAc by human O-GlcNAcase.

Authors:  Andrea C Rodriguez; Jennifer J Kohler
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

Review 9.  Structural characterization of the O-GlcNAc cycling enzymes: insights into substrate recognition and catalytic mechanisms.

Authors:  Cassandra M Joiner; Hao Li; Jiaoyang Jiang; Suzanne Walker
Journal:  Curr Opin Struct Biol       Date:  2019-01-30       Impact factor: 6.809

10.  Drosophila O-GlcNAcase Deletion Globally Perturbs Chromatin O-GlcNAcylation.

Authors:  Ilhan Akan; Dona C Love; Katryn R Harwood; Michelle R Bond; John A Hanover
Journal:  J Biol Chem       Date:  2016-03-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.